4 results about "Atresia" patented technology

A tissue expansion sleeve comprising a tube formed of woven polymer; the woven polymer forming helical trusses; and a biologically active material disposed on an outer surface of the tube.

The application relates to a method for establishing an early ovarian failure rat model, which comprises the following steps: taking healthy rats, and performing gavage on the rats according to a dosage of 10-20 mg / Kg of a phytostilbene preparation, wherein the dosage is the ratio of phytostilbene to the weight of the rats, and obtaining the early ovarian failure rat model after four days of administration. The early ovarian failure rat model is obtained by performing gavage on the rats after the phytostilbene preparation, the model is simple to establish, and the model establishment time is short. Through ovarian pathological observation, it can be seen that the simulated animal model has obvious ovary tissue damage, follicular granulosa cell destruction and apoptosis, and follicle atresia and other symptoms. The obtained model has good stability and repeatability. The phytostilbene is used to successfully establish the early ovarian failure rat model, lays a good foundation for establishing a stable early ovarian failure model for basic research, and provides a reliable method for the construction of the early ovarian failure model.

The invention provides an application of an E3 ubiquitin ligase RLIM gene inhibitor in preparation of a medicine for treating ovarian aging or injury. Experiments find that the expression level of the RLIM gene in the ovary is positively correlated with the aging degree, and the expression of the RLIM gene is remarkably improved along with age increase. In-vivo and in-vitro experiments show that ovarian granular cell senescence can be effectively delayed and ovarian functions can be improved by inhibiting RLIM expression, and particularly, the proportion of atresia follicles is reduced, the number of healthy follicles is increased, and serum AMH and E2 levels are remarkably improved. The pharmaceutical composition provided by the invention comprises a siRNA inhibitor (preferably, siRLIM-2) of specific targeting RLIM and a nano-liposome carrier, and efficient targeting delivery can be realized through tail vein injection. The treatment scheme has no toxic effect on important organs, is high in safety, and provides a new effective means for treatment of ovarian aging and related diseases.

The invention relates to an electrostatic spinning-photocuring composite tubular stent. The electrostatic spinning-photocuring composite tubular stent comprises a core, a shell and a coating layer, the core comprises polylactic acid and valine acid, the shell comprises polyvinyl butyral and a YAP agonist, and the coating layer comprises methacrylated hyaluronic acid and geniposide; the shell wraps the surface of the core, and the coating layer wraps the surface of the shell; the YAP agonist comprises C381 (C381). The preparation method comprises the following steps: preparation of the core-shell tubular stent and wrapping of the coating layer. According to the electrostatic spinning-photocuring composite tubular stent, a bile duct repair integrated platform which is free of acidification degradation, high in encapsulation efficiency, bionic in surface and capable of achieving three-medicine space-time synergy is achieved for the first time, and a breakthrough tissue engineering solution capable of being sewn, degraded and actively regenerated is provided for intractable bile diseases such as PSC and bile duct atresia.